Fujisawa Pharmaceutical Company, Ltd.

Astellas Pharma Gmbh

Wakunaga Pharmaceutical Co., Ltd.

Hideo Tsutsumi

Masayoshi Murata

Keiji Matsuda

Kohji Hattori

Takashi Nakajima

Takao Takaya

Nobuyoshi Yasuda

Fumiyuki Shirai

Hiromichi Itani

Toshiyuki Chiba

Yoshito Abe

Hironori Harada

Sunao Imada

Masataka Morita

Satoru Kuroda

Hiroaki Ohtake

Kazuyuki Hattori

Kazuya Fujita

Tatsuaki Morokata

Kazuo Sakane

Atsushi Akahane

Akito Tanaka

Akira Yazaki

Satoshi Inoue

Chiyoshi Kasahara

Yoshiteru Eikyu

Takeshi Terasawa

David Barrett

Masatoshi Minagawa

Seiichiro Tabuchi

Yoshihiro Kozuki

Taro Masunaga

Hohji Hattori

Yoshihiro Murakami

Nobuyuki Yasuda

To provide a useful compound as an active ingredient for a preventing and/or treating agent for rejection in the transplantation of an organ, bone marrow, or a tissue, an autoimmune disease, or the like, which has an excellent S1Pagonist activity. Since the compound of the invention has an S1Pagonist activity, it is useful as an active ingredient for a treating or preventing agent for a disease caused by unfavorable lymphocytic infiltration, for example, an autoimmune disease such as graft rejection in the transplantation of an organ, bone marrow, or a tissue, a graft-versus-host disease, rheumatic arthritis, multiple sclerosis, systemic lupus erythematosus, a nephrotic syndrome, encephalomeningitis, myasthenia gravis, pancreatitis, hepatitis, nephritis, diabetes, pulmonary disorder, asthma, atopic dermatitis, inflammatory bowel disease, atherosclerosis, ischemia-reperfusion injury, or an inflammatory disease, and further, a disease caused by the abnormal growth or accumulation of cells such as cancer and leukemia.

Hetero compound

This invention relates to novel N-hydroxyacrylamide compounds of formula (I) and pharmaceutically acceptable salts thereof. More particularly, it relates to novel N-hydroxyacrylamide compounds and pharmaceutically acceptable salts thereof which act as a HDAC inhibitor, to a pharmaceutical composition comprising the same and to a method of using the same therapeutically in the treatment and/or prevention of HDAC-related disease. 

Pyrazinyl hydroxyacrylamide compounds having an inhibitory effect on the activity of histone deacetylase

A pyrazine derivative of the following formula (I): 

Pyrazine derivatives and pharmaceutical use thereof

Sulphonyl compounds for use as linkers in solid phase and combinatorial synthesis

Substituted 3-pyrrolidinylthio-carbapenems as antimicrobial agents

Novel 3-pyrrolidinylthio-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid compounds and processes for their preparation are disclosed. These novel compounds have antimicrobial activity, and are useful as a medicament in the treatment of infectious diseases in human beings and animals.

3-pyrrolidinylthio-1-azabicyclo-[3.2.0]hept-2-ene-2-carboxylic acid

Certain tricyclic pyrido[3,2,1-ij]cinnoline-8-carboxylates, useful as

The invention relates to carbapenem derivatives useful as antimicrobial agents, more particularly to intermediate compounds for the preparations thereof of the formula ##STR1##

Processes for preparing carbapenem derivatives

1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid compounds

Novel carbapenem compounds of the formula: ##STR1## in which R.sup.1 is carboxy or protected carboxy,

Carbapenem compounds

The present invention concerns intermediates in the preparation of novel 3-pyrrolidinylthio-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid compounds and pharmaceutically acceptable salts thereof. The novel 3-pyrrolidinylthio-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid compounds and pharmaceutically acceptable salts thereof show antimicrobial activity.

3-pyrrolidinylthio-1-azabicyclo(3.2.0)-hept-2-ene-2-carboxylic acid

Novel 3-pyrrolidinylthio-1-azabiycyclo[3.2.0]hept-2-ene-2-carboxylic acid compounds and pharmaceutically acceptable salts thereof have antimicrobial activity and are useful as medicaments in the treatment of infectious diseases caused by pathogenic microorganisms.

3-Pyrrolidinylthio-1-azabicyclo-[3.2.0]hept-2-ene-2-carboxylic acid

1-Azabicyclo[3.2.0]hept-2-ene-2-carboxyic acids having antimicrobial activity have been prepared.

3-thio pyrrolidines are intermediates for carbapenams.

3-pyrrolidinylthio-1-azabicyclo-(3.2.0)hept-2-ene-2-carboxylic acid

Growing community of inventors

Toyonaka, Japan

Hideo Tsutsumi